# Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
Canonical URL: https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations-shareholder-communic-7dbf6e27
Ticker: ATOS
Company: Atossa Therapeutics, Inc.
Source: Atossa Therapeutics, Inc.
Published: 2025-09-17 12:00 EST
## Summary

Engagement to enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences...

## Article Body
Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company’s ongoing investor relations and communications initiatives. CORE IR specializes in emerging and established growth company strategies that enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiences.

Dr. Steven Quay, Chairman and CEO of Atossa, commented, “Our collaboration with CORE IR represents our continued commitment to drive value for our stakeholders and with the investment community. We are executing to plan and excited to communicate our progress with increasing market visibility. We believe CORE IR’s stewardship will help us better articulate our value proposition to existing and prospective shareholders.”

Under the terms of the engagement, CORE IR will provide a comprehensive suite of investor relations services including strategic messaging, non-deal roadshow support, investor targeting and outreach, and support for Atossa’s communication programs.

“We are gratified to partner with Atossa on their important journey,” said Scott Gordon, Co-Founder and President of CORE IR. “The Company is focused on advancing breast cancer prevention and treatment by pioneering new therapies with innovative science. We look forward to helping the company increase its engagement with the broader investment community.”

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is a highly potent SERM/D designed for use across the breast cancer spectrum, including risk-reduction, and treatment in the neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com .

Contacts:

Investors CORE IR ir@atossatherapeutics.com (212) 655-0924

Media Jules Abraham CORE IR pr@atossatherapeutics.com (212) 655-0924
## Recent Company News
- 2025-09-17 12:00 EST — [Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-appoints-core-ir-for-investor-relations-shareholder-communic-7dbf6e27) — Source: Atossa Therapeutics, Inc.
- 2025-04-30 12:45 EST — [Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-issuance-of-u-s-patent-no-12-281-056-including-58--540af8e3) — Source: Atossa Therapeutics, Inc.
- 2025-04-29 12:45 EST — [Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-proposes-potentially-groundbreaking-study-aimed-at-reducing--15eb7318) — Source: Atossa Therapeutics, Inc.
- 2025-03-25 12:00 EST — [Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-announces-full-year-2024-financial-results-and-provides-corp-d35fa88f) — Source: Atossa Therapeutics, Inc.
- 2025-03-20 13:13 EST — [Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results](https://biopharmsignal.com/news/ATOS/atossa-therapeutics-to-report-fourth-quarter-and-full-year-2024-financial-result-51da956e) — Source: Atossa Therapeutics, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)